Table 1.
Current glucagon containing anti-obesity drugs in development.
| Drug | Receptor target | Administration | Sequence modified | Receptor potency at human GLP1R and GCGR compared with native hormones. (Based on in vitro cAMP EC50 data) | GLP-1/GCGR ratio | Status | Ref | |
|---|---|---|---|---|---|---|---|---|
| GLP1R | GCGR | |||||||
| Cotadutide | GLP-1/glucagon | sc daily | Glucagon | 3-4 fold lower | ~8 fold lower | 5:1 | In Phase 2 for kidney disease | NCT04515849 (77) |
| SAR425899 | GLP-1/glucagon | sc daily | GLP-1 | ~1:1 | ~13 fold lower | 5:1 | Discontinued | (80) |
| MOD-6031 | GLP-1/glucagon | sc weekly | OXM | ? | ? | ? | Discontinued | NCT02692781 |
| G3215 | GLP-1/glucagon | sc continuous | OXM | ~1:1 fold lower | ~1:1 fold lower | 1:1 | Phase 1 | NCT02692040 |
| NNC9204-1177 | GLP-1/glucagon | sc weekly | ? | ? | ? | ? | Discontinued | NCT03308721 |
| Efinopegdutide | GLP-1/glucagon | sc weekly | OXM | ~3 fold lower | ~3 fold lower | 1:1 | Phase 2 for NAFLD | NCT03486392 (81) |
| BI 456906 | GLP-1/glucagon | sc weekly | Glucagon | ? | ? | ? | Phase 2 | NCT04153929 |
| OPK-88003/TT401 | GLP-1/glucagon | sc weekly | OXM | ? | ? | ? | Discontinued | NCT03406377 |
| MK-8521 | GLP-1/glucagon | sc daily | ? | ? | ? | ? | Discontinued | NCT02492763 |
| LY3305677 | GLP-1/glucagon | sc weekly | OXM | ? | ? | ? | Phase 1 | NCT03928379 |
| ALT-801 | GLP-1/glucagon | sc weekly | GLP-1 and glucagon | ? | ? | ? | Phase 1 | NCT04561245 (79) |
| JNJ-54728518 | GLP-1/glucagon | sc daily | OXM | ? | ? | ? | Phase 2 | NCT03486392 |
| HM15211 | GLP-1/GIP/Glucagon | sc weekly | Glucagon | ? | ? | ? | Phase 2 | NCT04505436 |
| NN9204-1706 | GLP-1/GIP/Glucagon | sc daily | ? | ? | ? | ? | Phase 1 | NCT03661879 |
| SAR441255 | GLP-1/GIP/Glucagon | sc daily | ? | ? | ? | ? | Discontinued | NCT04521738 |
| LY3437943 | GLP-1/GIP/Glucagon | sc weekly | ? | ? | ? | ? | Phase 1 | NCT04143802 |
?, unknown. NCT numbers from ClinicalTrials.gov.